| pubmed-article:9556129 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9556129 | lifeskim:mentions | umls-concept:C1254426 | lld:lifeskim |
| pubmed-article:9556129 | lifeskim:mentions | umls-concept:C0029431 | lld:lifeskim |
| pubmed-article:9556129 | lifeskim:mentions | umls-concept:C0380603 | lld:lifeskim |
| pubmed-article:9556129 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:9556129 | lifeskim:mentions | umls-concept:C1522492 | lld:lifeskim |
| pubmed-article:9556129 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:9556129 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:9556129 | pubmed:dateCreated | 1998-6-3 | lld:pubmed |
| pubmed-article:9556129 | pubmed:abstractText | We determined the effect of basic fibroblast growth factor (bFGF) on osteoclast-like cell (OCL) formation in bone marrow cultures using C57BL/6 mice. Cells were cultured for 7 days with or without bFGF at various concentrations or 10(-8) mol/L 1,25(OH)2 vitamin D3 [1,25(OH)2D3]. bFGF dose-dependently increased OCL formation per well (10(-10) mol/ L = 40 +/- 2; 10(-9) mol/L = 146 +/- 13; 10(-8) mol/L = 156 +/- 12) compared with control (< 7 per well). The effects of bFGF at 10(-9) and 10(-8) mol/L were similar to that of 10(-8) mol/L 1,25(OH)2D3 (154 +/- 11 per well). OCLs formed by bFGF were multinuclear, tartrate-resistant acid phosphatase (TRAP)-positive, expressed calcitonin receptors, and formed characteristic resorption pits. We also determined whether bFGF enhanced OCL formation during the early proliferative or late differentiating phases of the cultures. When bFGF (10(-8) mol/L) was added only on days 1-2 or days 3-4 of 6 day cultures, there was a significant increase in OCL formation. In contrast, when bFGF was added only on days 5-6 few OCLs formed. Addition of bFGF at days 1-6 or days 1-2 and days 5-6 caused similar increases in OCL formation, which were greater than OCL formation induced by treatment for days 1-2 or days 1-4. We examined the production of prostaglandin E2 (PGE2) in the cultures because bFGF is a potent stimulator of PGE2 synthesis in bone, and PGE2 stimulates OCL formation. bFGF treatment significantly increased PGE2 levels in 7 day cultures (controls = 1.4 +/- 0.1 nmol/L, 10(-8) mol/L bFGF = 132.5 +/- 0.7 nmol/L). In addition, treatment of marrow cultures with the prostaglandin synthesis inhibitors, indomethacin or NS-398 (both at 10(-6) mol/L), completely blocked bFGF-induced OCL formation. We conclude that bFGF stimulates OCL formation in C57BL/6 bone marrow cultures by mechanisms that require prostaglandin synthesis. This pathway is likely to be one mechanism by which bFGF stimulates resorption. | lld:pubmed |
| pubmed-article:9556129 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9556129 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9556129 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9556129 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9556129 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9556129 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9556129 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9556129 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9556129 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9556129 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9556129 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9556129 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9556129 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:9556129 | pubmed:issn | 8756-3282 | lld:pubmed |
| pubmed-article:9556129 | pubmed:author | pubmed-author:RaiszL GLG | lld:pubmed |
| pubmed-article:9556129 | pubmed:author | pubmed-author:LeeS KSK | lld:pubmed |
| pubmed-article:9556129 | pubmed:author | pubmed-author:LorenzoJJ | lld:pubmed |
| pubmed-article:9556129 | pubmed:author | pubmed-author:HurleyM MMM | lld:pubmed |
| pubmed-article:9556129 | pubmed:author | pubmed-author:BerneckerPP | lld:pubmed |
| pubmed-article:9556129 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9556129 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:9556129 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9556129 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9556129 | pubmed:pagination | 309-16 | lld:pubmed |
| pubmed-article:9556129 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:9556129 | pubmed:meshHeading | pubmed-meshheading:9556129-... | lld:pubmed |
| pubmed-article:9556129 | pubmed:meshHeading | pubmed-meshheading:9556129-... | lld:pubmed |
| pubmed-article:9556129 | pubmed:meshHeading | pubmed-meshheading:9556129-... | lld:pubmed |
| pubmed-article:9556129 | pubmed:meshHeading | pubmed-meshheading:9556129-... | lld:pubmed |
| pubmed-article:9556129 | pubmed:meshHeading | pubmed-meshheading:9556129-... | lld:pubmed |
| pubmed-article:9556129 | pubmed:meshHeading | pubmed-meshheading:9556129-... | lld:pubmed |
| pubmed-article:9556129 | pubmed:meshHeading | pubmed-meshheading:9556129-... | lld:pubmed |
| pubmed-article:9556129 | pubmed:meshHeading | pubmed-meshheading:9556129-... | lld:pubmed |
| pubmed-article:9556129 | pubmed:meshHeading | pubmed-meshheading:9556129-... | lld:pubmed |
| pubmed-article:9556129 | pubmed:meshHeading | pubmed-meshheading:9556129-... | lld:pubmed |
| pubmed-article:9556129 | pubmed:meshHeading | pubmed-meshheading:9556129-... | lld:pubmed |
| pubmed-article:9556129 | pubmed:meshHeading | pubmed-meshheading:9556129-... | lld:pubmed |
| pubmed-article:9556129 | pubmed:meshHeading | pubmed-meshheading:9556129-... | lld:pubmed |
| pubmed-article:9556129 | pubmed:meshHeading | pubmed-meshheading:9556129-... | lld:pubmed |
| pubmed-article:9556129 | pubmed:meshHeading | pubmed-meshheading:9556129-... | lld:pubmed |
| pubmed-article:9556129 | pubmed:meshHeading | pubmed-meshheading:9556129-... | lld:pubmed |
| pubmed-article:9556129 | pubmed:meshHeading | pubmed-meshheading:9556129-... | lld:pubmed |
| pubmed-article:9556129 | pubmed:meshHeading | pubmed-meshheading:9556129-... | lld:pubmed |
| pubmed-article:9556129 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9556129 | pubmed:articleTitle | Basic fibroblast growth factor induces osteoclast formation in murine bone marrow cultures. | lld:pubmed |
| pubmed-article:9556129 | pubmed:affiliation | The University of Connecticut Health Center, Farmington 06030-1850, USA. hurley@nsol.uchc.edu | lld:pubmed |
| pubmed-article:9556129 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9556129 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:9556129 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9556129 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9556129 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9556129 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9556129 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9556129 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9556129 | lld:pubmed |
